Esko Kankuri

Dr. Esko Kankuri

Department of Pharmacology, University of Helsinki, Helsinki, Finland
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2023 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
RMRafael Moliner
Rafael Moliner
MGMykhailo Girych
Mykhailo Girych
CBCecilia A. Brunello
Cecilia A. Brunello
VKVera Kovaleva
Vera Kovaleva
CBCaroline Biojone
Caroline Biojone
ECEero Castren
Eero Castren
Psychedelics produce fast and persistent antidepressant effects and induce neuroplasticity resembling the effects of clinically approved antidepressants. We recently reported that pharmacologically diverse antidepressants, including fluoxetine and ketamine, act by binding to TrkB, the receptor for BDNF. Here we show that lysergic acid diethylamide (LSD) and psilocin directly bind to TrkB with affinities 1,000-fold higher than those for other antidepressants, and that psychedelics and antidepressants bind to distinct but partially overlapping sites within the transmembrane domain of TrkB dimers. The effects of psychedelics on neurotrophic signaling, plasticity and antidepressant-like behavior in mice depend on TrkB binding and promotion of endogenous BDNF signaling but are independent of serotonin 2A receptor (5-HT2A) activation, whereas LSD-induced head twitching is dependent on 5-HT2A and independent of TrkB binding. Our data confirm TrkB as a common primary target for antidepressants and suggest that high-affinity TrkB positive allosteric modulators lacking 5-HT2A activity may retain the antidepressant potential of psychedelics without hallucinogenic effects.

29 September 2022 in Cells
Verified
Journal Article
Open access
PDF file
MBMatthew Burgess
Matthew Burgess
FVFranklin Valdera
Franklin Valdera
DVDavid Varon
David Varon
EKEsko Kankuri
Esko Kankuri
KNKristo Nuutila
Kristo Nuutila
Burn are diverse and complex injuries that not only have local effects but also serious systemic consequences through severe and prolonged inflammatory response. They are caused by heat, electricity, friction, chemicals, or radiation and are commonly divided into superficial, superficial partial-, deep partial- and full-thickness injuries. The severity of the burn depends mainly on the size and depth of the injury but also on location, age, and underlying systemic diseases. A prolonged and strong immune response makes major burns even worse by causing multiple systemic effects including damage to the heart, lungs, blood vessels, kidneys, and other organs. Burns that do not require surgical excision, superficial and superficial partial-thickness, follow the known progression of wound healing (inflammation, proliferation, remodeling), whilst deep partial- and full thickness injuries requiring excision and grafting do not. For these burns, intervention is required for optimal coverage, function, and cosmesis. Annually millions of people worldwide suffer from burns associated with high morbidity and mortality. Fortunately, over the past decades, burn care has significantly improved. The improvement in understanding the pathophysiology of burn injury and burn wound progression has led to developments in skin grafting, fluid resuscitation, infection control and nutrition This review article focuses on the immune and regenerative responses following burn injury. In the Introduction, we describe the epidemiology of burns and burn pathophysiology. The focus of the following chapter is on systemic responses to burn injury. Next, we define the immune response to burns introducing all the different cell types involved. Subsequently, we discuss the regenerative cell response to burns as well as some of the emerging novel treatments in the battle against burns.

21 February 2018 in Advanced Materials
Verified
Journal Article
Open access
PDF file
VJVille Jokinen
Ville Jokinen
EKEsko Kankuri
Esko Kankuri
SHSasha Hoshian
Sasha Hoshian
SFSami Franssila
Sami Franssila
RRRobin H. A. Ras
Robin H. A. Ras
Superhydrophobic surfaces repel water and, in some cases, other liquids as well. The repellency is caused by topographical features at the nano‐/microscale and low surface energy. Blood is a challenging liquid to repel due to its high propensity for activation of intrinsic hemostatic mechanisms, induction of coagulation, and platelet activation upon contact with foreign surfaces. Imbalanced activation of coagulation drives thrombogenesis or formation of blood clots that can occlude the blood flow either on‐site or further downstream as emboli, exposing tissues to ischemia and infarction. Blood‐repellent superhydrophobic surfaces aim toward reducing the thrombogenicity of surfaces of blood‐contacting devices and implants. Several mechanisms that lead to blood repellency are proposed, focusing mainly on platelet antiadhesion. Structured surfaces can: (i) reduce the effective area exposed to platelets, (ii) reduce the adhesion area available to individual platelets, (iii) cause hydrodynamic effects that reduce platelet adhesion, and (iv) reduce or alter protein adsorption in a way that is not conducive to thrombus formation. These mechanisms benefit from the superhydrophobic Cassie state, in which a thin layer of air is trapped between the solid surface and the liquid. The connections between water‐ and blood repellency are discussed and several recent examples of blood‐repellent superhydrophobic surfaces are highlighted.

1 March 2019 in Cell Reports
Verified
Journal Article
Open access
SSSimona Selberg
Simona Selberg
DBDaria Blokhina
Daria Blokhina
MAMaria Aatonen
Maria Aatonen
PKPertti Koivisto
Pertti Koivisto
ASAntti Siltanen
Antti Siltanen
MKMati Karelson
Mati Karelson
Chemical modifications of RNA provide an additional, epitranscriptomic, level of control over cellular functions. N-6-methylated adenosines (m6As) are found in several types of RNA, and their amounts are regulated by methyltransferases and demethylases. One of the most important enzymes catalyzing generation of m6A on mRNA is the trimer N-6-methyltransferase METTL3-14-WTAP complex. Its activity has been linked to such critical biological processes as cell differentiation, proliferation, and death. We used in silico-based discovery to identify small-molecule ligands that bind to METTL3-14-WTAP and determined experimentally their binding affinity and kinetics, as well as their effect on enzymatic function. We show that these ligands serve as activators of the METTL3-14-WTAP complex.

9 May 2005 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
EME. Myllyluoma
E. Myllyluoma
LVL. Veijola
L. Veijola
TAT. Ahlroos
T. Ahlroos
STS. Tynkkynen
S. Tynkkynen
EKEsko Kankuri
Esko Kankuri
RKRiitta A Korpela
Riitta A Korpela

1 April 2022 in Pharmacology & Therapeutics
Verified
Journal Article
Open access
SGSonia Gera
Sonia Gera
EKEsko Kankuri
Esko Kankuri
Karin KogermannKarin Kogermann
Karin Kogermann
Antimicrobial peptides (AMPs) are potent, mostly cationic, and amphiphilic broad-spectrum host defense antimicrobials that are produced by all organisms ranging from prokaryotes to humans. In addition to their antimicrobial actions, they modulate inflammatory and immune responses and promote wound healing. Although they have clear benefits over traditional antibiotic drugs, their wide therapeutic utilization is compromised by concerns of toxicity, stability, and production costs. Recent advances in nanotechnology have attracted increasing interest to unleash the AMPs' immense potential as broad-spectrum antibiotics and anti-biofilm agents, against which the bacteria have less chances to develop resistance. Topical application of AMPs promotes migration of keratinocytes and fibroblasts, and contributes significantly to an accelerated wound healing process. Delivery of AMPs by employing nanotechnological approaches avoids the major disadvantages of AMPs, such as instability and toxicity, and provides a controlled delivery profile together with prolonged activity. In this review, we provide an overview of the key properties of AMPs and discuss the latest developments in topical AMP therapy using nanocarriers. We use chronic hard-to-heal wounds-complicated by infections, inflammation, and stagnated healing-as an example of an unmet medical need for which the AMPs' wide range of therapeutic actions could provide the most potential benefit. The use of innovative materials and sophisticated nanotechnological approaches offering various possibilities are discussed in more depth.